Huang’s group found that HDAC inhibitor sulforaphane suppressed the proliferation of BC cells via blocking activity of upstream transcription factor 1 (USF1) and promoting ubiquitination degradation of LSD1, and LSD1 inhibitor significantly sensitized sulforaphane to BC in cellulo and in vivo (Cao et al., 2018), which inhibited that the combined therapy or discovery of LSD1/HDAC5 inhibitors is a potential strategy for BC treatment. Here, KDM1A is linked to breast cancer.